Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy

[1]  A. Khorana,et al.  Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival , 2021, Journal for ImmunoTherapy of Cancer.

[2]  M. Preusser,et al.  Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. , 2020, Blood.

[3]  L. Saba,et al.  Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. , 2020, Thrombosis research.

[4]  M. Milowsky,et al.  Underrepresentation of genitourinary cancers in studies of venous thromboembolism (VTE) prophylaxis. , 2020 .

[5]  E. Espinosa,et al.  Incidence of vascular thromboembolism events in cancer patients receiving immunotherapy: A single institution experience , 2019, Annals of Oncology.

[6]  R. Berger,et al.  Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. , 2019, European journal of cancer.

[7]  A. Khorana,et al.  Venous Thromboembolism in Cancer Patients Receiving Immunotherapy , 2018, Blood.

[8]  J. Pinthus,et al.  Thromboembolism in Patients with Bladder Cancer: Incidence, Risk Factors and Prevention , 2018, Bladder cancer.

[9]  S. Vesely,et al.  Incidence of Vascular Thromboembolic Events in Patients Receiving Immunotherapy: A Single Institution Experience , 2017 .

[10]  H. Kamel,et al.  Risk of Arterial Thromboembolism in Patients With Cancer. , 2017, Journal of the American College of Cardiology.

[11]  A. Hegde,et al.  PS01.64: Effect of Anti‐PD1 Therapy on the Incidence of Thromboembolic Events in Lung Cancer: Topic: Medical Oncology , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  H. Wiendl,et al.  Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice , 2014, PloS one.

[13]  A. Khorana,et al.  Risk Assessment for Thrombosis in Cancer , 2014, Seminars in Thrombosis & Hemostasis.

[14]  A. Khorana,et al.  Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States , 2013, ClinicoEconomics and outcomes research : CEOR.

[15]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[16]  A. Kakkar,et al.  Cancer-associated thrombosis , 2010, British Journal of Cancer.

[17]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[18]  H. Chew,et al.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.

[19]  W. Ghali,et al.  Venous thromboembolism according to age: the impact of an aging population. , 2004, Archives of internal medicine.

[20]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[21]  J. Heit,et al.  Risk factors for venous thromboembolism. , 2003, Clinics in chest medicine.

[22]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[23]  W. Kisiel,et al.  Fibrinogen-fibrin transformation in situ in renal cell carcinoma. , 1990, Anticancer research.